Drug Profile
Onychomycosis therapy - Arpida
Alternative Names: TLT therapy - Arpida; Transungual LaserTherapy - ArpidaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Developer Evolva Holding SA
- Class Amines; Antifungals; Naphthalenes; Skin disorder therapies; Small molecules
- Mechanism of Action Squalene monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Onychomycosis
Most Recent Events
- 14 Dec 2009 Evolva SA has merged with Arpida to form Evolva Holding SA
- 22 Jan 2008 Phase-III clinical trials in Onychomycosis in European Union (Topical)
- 18 Jul 2007 Clinical trials in Onychomycosis in Europe (Topical)